Well, PT=bonefishman, was this mere happenstance that we cross paths this early morn? Whatever, I am going to call zumantu's attention to you and particularly your cited blog over on the AMRN board---you will recall that Vascepa, AMRN's capsule containing its pufa known as EPA in 96% content, is nearing its 1st interim look in its phase 3 trial. A slew of CVD markers will be looked at--including those I posted on the AMARIN IHUB board a few weeks back that reflect LabCorp and Quest Diagnostic lipid panel data achieved after off- label use of Vascepa since 4/01/2013. Those markers are also anti-inflammatory markers--indicators of lack of inflammation.
I will read the cited blog tomorrow. We already have email addresses and phone nos. We should arrange our usual lunch with hump4 and Bungler soon, if all are available.
Was it also coincidental that I was watching the 2015 flick "The Age of Adaline" while typing this missive? Pure fiction of course.
Market Data 
Markets 
AI
